Mortality did not decrease, compared with placebo, in patients with chronic obstructive pulmonary disease (COPD) and cardiovascular disease risk who took the inhaled corticosteroid fluticasone furoate ...

HealthDay News — A combination of fluticasone furoate and vilanterol reduces the rate of moderate or severe exacerbations among patients with chronic obstructive pulmonary disease (COPD), according to ...

Fluticasone furoate/vilanterol (FF/VI) improved FEV1 but did not improve morning peak expiratory flow in pediatric patients with uncontrolled asthma. Among pediatric patients with uncontrolled asthma, ...

HealthDay News — Regular use of fluticasone furoate (FF), either alone or in combination with vilanterol (VI), appears to reduce the rate of forced expiratory volume in one second (FEV1) decline in ...

The Phase 3 trial included a total of 1,810 patients with advanced COPD GlaxoSmithKline and Innoviva announced top-line results from the Phase 3 FULFIL study ...

Using a fluticasone furoate nasal spray for treatment of obstructive sleep apnea in children appears to reduce production of certain inflammatory cell proteins that may play a role in development of ...

LONDON, Aug. 20, 2014 /PRNewswire/ -- GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta ® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS ...

Triple therapy delivered in a single inhaler reduces moderate to severe exacerbations in chronic obstructive pulmonary disease (COPD) to a greater extent than dual-inhaler therapy in patients at high ...

In a recent article published in the New England Journal of Medicine, researchers presented the findings of an ongoing double-blinded, randomized, placebo-controlled platform-protocol clinical trial, ...

DUBLIN--(BUSINESS WIRE)--The "Breo Ellipta" report has been added to ResearchAndMarkets.com's offering. Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol ...

LONDON and SOUTH SAN FRANCISCO, CA--(MARKET WIRE)--Feb 4, 2009 -- GlaxoSmithKline (GSK) and Theravance, Inc. (NasdaqGM:THRX - News) today announced positive results from three, separate phase 2b ...